Investor Relations - Curis

Month Year

Investor Alerts

May 29, 2018

Curis Announces Effectiveness of 1-for-5 Reverse Stock Split

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its...
May 24, 2018

Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

- Dr. David Tuck, CMO, to retire and return to academia -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that...
May 22, 2018

Curis Announces 1-for-5 Reverse Stock Split

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its...
May 3, 2018

Curis Reports First Quarter 2018 Financial Results

-- Management to host conference call today at 8:30 a.m. EDT --

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today reported its...
Apr 26, 2018

Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the...
Apr 6, 2018

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced...
Mar 8, 2018

Curis Reports Fourth Quarter and Year-End 2017 Financial Results

-- Management to host conference call today at 8:30 a.m. EST --

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today reported its...
Mar 5, 2018

Curis to Present at Cowen & Company 38th Annual Health Care Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali...
Mar 1, 2018

UPDATED -- Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018

In the news release, Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018, issued 01-Mar-2018 by Curis, Inc. over PR Newswire, we are...
Jan 17, 2018

Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced...
Nov 7, 2017

Curis Reports Third Quarter 2017 Financial Results

Management to host conference call today at 8:30 a.m. EST

LEXINGTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Nov 3, 2017

Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

LEXINGTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Nov 1, 2017

Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017

LEXINGTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Sep 22, 2017

Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

LEXINGTON, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
Sep 14, 2017

Curis Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its...
Sep 11, 2017

Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017

Results from 34 Patients Demonstrate Positive Safety Profile and Support Decision to Expand Development

LEXINGTON, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
Sep 6, 2017

Curis to Present at the Baird 2017 Global Healthcare Conference

LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
Aug 31, 2017

Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress

LEXINGTON, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Aug 16, 2017

Curis to Present at the Noble Financial Small Cap Equity Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 16, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
Aug 3, 2017

Curis Reports Second Quarter 2017 Financial Results

Management to host conference call today at 8:30 a.m. EDT

LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Jul 26, 2017

Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017

LEXINGTON, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jul 5, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Jun 1, 2017

Curis to Present at the Jefferies Healthcare Conference

LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
May 25, 2017

Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting

LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
May 4, 2017

Curis Reports First Quarter 2017 Financial Results

Management to host conference call today at 8:30 a.m. EDT

LEXINGTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Apr 28, 2017

Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017

LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 5, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Mar 30, 2017

Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting

LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Mar 16, 2017

Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
Mar 9, 2017

Curis Reports Fourth Quarter and Year-End 2016 Financial Results

Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge® Royalty

LEXINGTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Mar 7, 2017

Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017

LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Mar 1, 2017

Curis to Present at the Cowen and Company 37th Annual Health Care Conference

LEXINGTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 17, 2017

Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 7, 2017

Curis to Release Second Quarter 2007 Financial Results and Hold Conference Call on February 14, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
Jan 9, 2017

Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Jan 6, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Nov 28, 2016

Curis Announces Full Approval of Roche's Erivedge® in the European Union

LEXINGTON, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Nov 14, 2016

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Nov 9, 2016

Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170's Phase 1 Trial at the SITC 2016 Conference

LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Nov 3, 2016

Curis Reports Third Quarter 2016 Financial Results

Management to host conference call today at 8:30 a.m. EDT

LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Oct 27, 2016

Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016

LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Oct 11, 2016

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration

LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Oct 11, 2016

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Sep 16, 2016

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Sep 7, 2016

Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement

Curis to issue to 10.2M shares of Common Stock to Aurigene at $2.40 per share

LEXINGTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Aug 31, 2016

Curis to Present at Baird's 2016 Global Healthcare Conference

LEXINGTON, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Aug 4, 2016

Curis Reports Second Quarter 2016 Financial Results

Management to host conference call today at 8:30 a.m. EDT

LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Jul 28, 2016

Curis to Release Second Quarter 2016 Financial Results and Hold Conference Call on August 4, 2016

LEXINGTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jun 21, 2016

Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints

LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Jun 2, 2016

Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting

LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Jun 2, 2016

Curis to Present at the Jefferies Healthcare Conference

LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jun 1, 2016

Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints

LEXINGTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
May 9, 2016

Curis Reports First Quarter 2016 Financial Results

Management to host conference call today at 8:30 a.m. EDT

LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
May 2, 2016

Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016

Lexington, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Apr 20, 2016

Curis and Aurigene Present Preclinical Data from Multiple Programs at AACR Annual Meeting

LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Apr 10, 2016

Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting

LEXINGTON, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Apr 4, 2016

Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015

LEXINGTON, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Mar 30, 2016

Curis Announces Expansion of Executive Team

James Dentzer joins Curis as Chief Financial and Chief Administrative Officer

LEXINGTON, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Mar 8, 2016

Curis to Present at the 28th Annual Roth Conference

LEXINGTON, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Mar 1, 2016

Curis to Present at the Cowen and Company 36th Annual Health Care Conference

LEXINGTON, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 29, 2016

Curis Reports Fourth Quarter and Year-End 2015 Financial Results

LEXINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 22, 2016

Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016

LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 17, 2016

Curis to Present at the 2016 RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 1, 2016

Curis to Present at the BIO CEO & Investor Conference

LEXINGTON, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Dec 5, 2015

Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting

Curis expects to initiate a randomized Phase 2 trial in patients with relapsed/refractory DLBCL with MYC alterations

LEXINGTON, Mass., Dec. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Dec 2, 2015

Curis to Present at the Oppenheimer 26th Annual Healthcare Conference

LEXINGTON, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 8, 2015

Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 8, 2015

Curis Reports Third Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 a.m. EST

LEXINGTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 5, 2015

Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 2, 2015

Curis to Release Third Quarter 2015 Financial Results and Hold Conference Call on November 9, 2015

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Nov 2, 2015

Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Oct 19, 2015

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

Company exercises options under Aurigene collaboration to license orally available small molecules for immuno-oncology and precision oncology

LEXINGTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Oct 14, 2015

Curis to Present at the BIO Investor Forum

LEXINGTON, Mass., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Sep 2, 2015

Curis to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jul 30, 2015

Curis to Release Second Quarter 2015 Financial Results and Hold Conference Call on August 6, 2015

LEXINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jul 6, 2015

Curis Reports Second Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 a.m. EDT

LEXINGTON, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Jun 10, 2015

Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

LEXINGTON, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 31, 2015

Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting

CUDC-907 (HDAC and PI3K Inhibitor) Demonstrates Objective Responses, Including Complete Responses, in Patients With Relapsed/ Refractory DLBCL

LEXINGTON, Mass., May 31, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 26, 2015

Curis to Present at the Jefferies 2015 Healthcare Conference

LEXINGTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 20, 2015

Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

LEXINGTON, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
May 7, 2015

Curis Reports First Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 a.m. EDT

LEXINGTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 30, 2015

Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015

LEXINGTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 22, 2015

Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting

Collaborator Aurigene Presents Data From Its IRAK-4 Program

LEXINGTON, Mass., April 22, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 14, 2015

Curis Announces Presentation of Data from CUDC-427 and IRAK-4 Programs at AACR Annual Meeting

LEXINGTON, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Apr 5, 2015

Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

LEXINGTON, Mass., April 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Mar 3, 2015

Curis to Present at the 27th Annual Roth Conference

LEXINGTON, Mass., March 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Mar 2, 2015

Curis Announces Closing of Public Offering of Common Stock

LEXINGTON, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today the closing of its previously announced public offering of common stock. Curis sold 25,090,908 shares...
Feb 25, 2015

Curis Prices Public Offering of Common Stock

LEXINGTON, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at...
Feb 25, 2015

Curis to Present at the Cowen and Company 35th Annual Health Care Conference

LEXINGTON, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 24, 2015

Curis Reports Fourth Quarter and Year-End 2014 Financial Results

LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Feb 24, 2015

Curis Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today that it has commenced an underwritten public offering of shares of its common stock. In connection...
Feb 3, 2015

Curis to Present at the 2015 Bio CEO and Investor Conference

LEXINGTON, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jan 21, 2015

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor

LEXINGTON, Mass. and BANGALORE, India, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
Nov 26, 2014

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 17, 2014

Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors

Trial Expected to Enroll Patients With Hormone Receptor Positive Breast Cancer and Patients With Midline Carcinoma With NUT Rearrangement

LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 12, 2014

Curis to Present at the Stifel 2014 Healthcare Conference

LEXINGTON, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 10, 2014

Curis Reports Third Quarter 2014 Financial Results and Pipeline Update

Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients

LEXINGTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Nov 3, 2014

Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014

LEXINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
Oct 28, 2014

Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule

LEXINGTON, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Oct 2, 2014

Curis Announces CUDC-907 Development Program Advancements

Expansion cohorts opened to enroll patients with relapsed/refractory Diffuse Large B-Cell Lymphoma and Multiple Myeloma

LEXINGTON, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...

Show per page